Related Experiment Video

Updated: Jul 18, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Targeting lymphoma cells and their microenvironment with novel antibodies

Amanda Wedgwood1, Anas Younes

  • 1Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

Clinical Lymphoma & Myeloma
|November 15, 2006
PubMed

Insights

Novel monoclonal antibodies are revolutionizing lymphoma treatment by targeting cancer cells to reduce toxicity. Further research aims to combine these therapies for improved cure rates in Hodgkin

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Lymphoma treatment requires reducing toxicity and improving cure rates.
  • Novel therapies are essential for advancing lymphoma care.
  • Monoclonal antibodies offer targeted approaches to cancer treatment.

Purpose of the Study:

  • To evaluate the impact of novel monoclonal antibodies in lymphoma treatment.
  • To explore antibody therapies targeting malignant cells and the tumor microenvironment.
  • To encourage research into combining antibody therapies with other targeted treatments.

Main Methods:

  • Review of investigational monoclonal antibody therapies for lymphoma.
  • Analysis of antibody strategies targeting tumor cells and the microenvironment.
  • Assessment of potential combination therapies with monoclonal antibodies.

Main Results:

  • Monoclonal antibodies show significant influence in treating Hodgkin's and non-Hodgkin's lymphoma.
  • Targeted antibody therapies spare normal cells, potentially reducing treatment toxicity.
  • Investigational therapies include those targeting malignant cells and the tumor microenvironment.

Conclusions:

  • Monoclonal antibodies represent a promising advancement in lymphoma therapy.
  • Targeted antibody approaches may improve lymphoma cure rates while minimizing side effects.
  • Further investigation into combination therapies and integration into standard care is warranted.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...